CellCentric Secures $35 Million in Funding for Groundbreaking Cancer Therapy targeting p300 and CBP

CellCentric is thrilled to announce the successful raising of $35 million in its latest funding round, a significant boost that will accelerate the development of its groundbreaking oral drug, Inobrodib. As the first small molecule therapy specifically targeting the twin proteins p300 and CBP, Inobrodib represents a potential game-changer in oncology. These acetyl transferases are crucial gene-activating proteins linked to the progression of several aggressive cancers. With this new funding, CellCentric aims to advance Inobrodib through its ongoing Phase I/II clinical trials, evaluating its efficacy in treating both solid tumors and hematological malignancies, such as blood cancers. Currently, these patient populations face considerable challenges, with many limited to few existing treatment options. By focusing on such urgent clinical unmet needs, CellCentric is poised to offer a novel therapy that not only has the potential to improve patient outcomes but also to address a substantial gap in cancer care. The influx of capital will be utilized to further clinical trial operations, expand research efforts, and support necessary regulatory submissions. With the commitment of our investors and the dedication of our team, we are optimistic about bringing Inobrodib to patients who desperately need innovative solutions in their cancer battle. This funding round marks an exciting step forward for CellCentric as we continue our mission to transform the landscape of cancer treatment.